Mereo BioPharma Statistics
Share Statistics
Mereo BioPharma has 159M
shares outstanding. The number of shares has increased by 453.03%
in one year.
| Shares Outstanding | 159M |
| Shares Change (YoY) | 453.03% |
| Shares Change (QoQ) | 401.33% |
| Owned by Institutions (%) | 14.96% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 31,860 |
| FTD / Avg. Volume | 2.26% |
Short Selling Information
The latest short interest is 7.95M, so 5% of the outstanding
shares have been sold short.
| Short Interest | 7.95M |
| Short % of Shares Out | 5% |
| Short % of Float | 7.03% |
| Short Ratio (days to cover) | 7.57 |
Valuation Ratios
The PE ratio is -11.97 and the forward
PE ratio is -73.
Mereo BioPharma's PEG ratio is
0.12.
| PE Ratio | -11.97 |
| Forward PE | -73 |
| PS Ratio | 0 |
| Forward PS | 1.8 |
| PB Ratio | 8.49 |
| P/FCF Ratio | -15.44 |
| PEG Ratio | 0.12 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Mereo BioPharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.4,
with a Debt / Equity ratio of 0.11.
| Current Ratio | 5.4 |
| Quick Ratio | 5.4 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | -0.14 |
| Debt / FCF | -0.19 |
| Interest Coverage | -34.56 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,201,472.22 |
| Employee Count | 36 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 18.2K |
| Effective Tax Rate | -0.04% |
Stock Price Statistics
The stock price has increased by -38.44% in the
last 52 weeks. The beta is 0.47, so Mereo BioPharma's
price volatility has been higher than the market average.
| Beta | 0.47 |
| 52-Week Price Change | -38.44% |
| 50-Day Moving Average | 2.3 |
| 200-Day Moving Average | 3.33 |
| Relative Strength Index (RSI) | 43.93 |
| Average Volume (20 Days) | 1,407,424 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -47.36M |
| Net Income | -43.25M |
| EBITDA | -47.36M |
| EBIT | -44.62M |
| Earnings Per Share (EPS) | -0.29 |
Full Income StatementBalance Sheet
The company has 69.8M in cash and 6.43M in
debt, giving a net cash position of 63.37M.
| Cash & Cash Equivalents | 69.8M |
| Total Debt | 6.43M |
| Net Cash | 63.37M |
| Retained Earnings | -462.88M |
| Total Assets | 68.32M |
| Working Capital | 59.4M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -32.83M
and capital expenditures -699K, giving a free cash flow of -33.53M.
| Operating Cash Flow | -32.83M |
| Capital Expenditures | -699K |
| Free Cash Flow | -33.53M |
| FCF Per Share | -0.05 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
